GlassScriptPhysician profile
Antonio H Nucum, JR.
NPI 1164431540
$15,277.53
in general payments reported to CMS, 2019-2025
29 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,158 · 2020: $1,457 · 2021: $2,482 · 2022: $1,336 · 2023: $2,328 · 2024: $2,347 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,832 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,831.90 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $2,160.78 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,937.16 | 2019-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Janssen Pharmaceuticals, INC | $1,297.47 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $1,200.07 | 2019-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $1,044.51 | 2019-2022 | |
| Abbvie INC. | $971.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $860.23 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $823.44 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $746.85 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Validus Pharmaceuticals LLC | $694.85 | 2019-2025 | Equetro, Equetro, Raldesy |
| Ironshore Pharmaceuticals INC. | $659.88 | 2019-2024 | Jornay Pm |
| Corium, LLC | $653.33 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $422.28 | 2019-2025 | Fanapt |
| Allergan, INC. | $352.94 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $351.42 | 2022-2025 | Qelbree, Qelbree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $198.44 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $176.95 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $104.44 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Avanir Pharmaceuticals, INC. | $96.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.77 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $85.06 | 2024-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $81.10 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $56.54 | 2022-2024 | Quviviq |
| Indivior INC. | $56.29 | 2024 | Perseris |
| Shire North American Group INC | $53.64 | 2019 | |
| Vertical Pharmaceuticals, LLC | $35.73 | 2019-2020 | |
| Bausch Health US, LLC | $27.58 | 2019-2021 | |
| Owp Pharmaceuticals, INC. | $22.60 | 2025 | Subvenite |
| Adlon Therapeutics L.P. | $19.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Nucum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.